China Hepatitis Drugs Market Review by AMID Now Available at MarketPublishers.com
25 Apr 2012 • by Natalie Aster
LONDON – Over the last ten years China's demand for hepatitis drugs has grown at a fast pace. In the next five years, both production and demand are expected to keep on growing. Because treatment with nucleoside/nucleotide analogues is typically long-term (in many cases, lifelong), even steady diagnosis and drug-treatment rates would generate sizable near-term expansion of this market. Government-sponsored improvements to the healthcare system and increasing economic prosperity among the Chinese population have also added to this market growth.
Most recent report “Chinese Markets for Hepatitis Drugs” worked out by Asia Market Information & Development Co. (AMID) has been recently published by Market Publishers Ltd.
Chinese Markets for Hepatitis Drugs
Published: April, 2012
Price: US$ 4.000,00
The research report provides true and unprejudiced insights into the hepatitis drugs market in China. It examines a number of key issues including the country’s economic trends, investment environment, industry development, supply and demand, industry capacity and structure, marketing channels and major industry participants. Furthermore, historical data (2001, 2006 and 2011) and long-term forecasts through 2016 and 2021; as well as elaborate profiles of top producers of hepatitis drugs in China are also available.
More new market research reports by the publisher can be found at AMID page.